ClinicalTrials.gg
RecruitingNCT07850869Updated Sep 30, 2026

A Real-World Observational Study of Intratumoral H101 Oncolytic Adenovirus Combined With Immune Checkpoint Inhibitors for Advanced Metastatic Breast Cancer

An observational study in Breast Cancer (Locally Advanced or Metastatic), sponsored by Jie Yuan,MD. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Jie Yuan,MD · Observational

Updated Sep 30, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
15
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,928 studies in Breast Neoplasms with a site in China — 866 open to participants now, 1,064 under way, 210 of them phase 3. Breast Neoplasms · China.

Planned enrollment
401st of 407
15 · median 240
Started
2026
with 184 others
Observational
407 of 1,928
177 open now
Primary completion
2028-02
later than 809 of 1,063 live
Registered
1,901st of 1,928
by date

Among the 1,928 studies in Breast Neoplasms with a site in China, this one is the 401st largest by planned enrollment of the 407 observational ones that give a count, is one of 185 that started in 2026, is one of 407 observational ones, reaches primary completion later than 809 of the 1,063 other live ones, and was the 1,901st registered.

Breast Neoplasms

14,832 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

866 of the 1,928 studies in Breast Neoplasms with a site in China are open now. Recruiting first, the newest first:

860 more — sign in →

All 866 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,928 studies in Breast Neoplasms with a site in China, or all of them as a file.
02

Study summary

This prospective, single-center, open-label, real-world observational study plans to enroll 10-15 patients with advanced (Stage IV) breast cancer who have failed multiple prior therapies [aged 18-75, Eastern Cooperative Oncology Group Performance Status Clinical Classification(ECOG) 0-2, with measurable and injectable lesions]. It aims to preliminarily evaluate the antitumor activity, safety, and immune-microenvironment modulation of intratumoral H101(Recombinant Human Adenovirus Type 5 Injection) oncolytic virus combined with immune checkpoint inhibitors (ICIs) in real-world practice. The regimen is determined by physicians based on clinical status and multidisciplinary input, but follows a standardized framework: 2- to 3-week cycles; H101 injected on day 1 (dose stratified by lesion size), with ICI infusion started 7±2 days later, for 4 planned cycles. Paired tumor biopsies (when feasible) and peripheral blood are collected at baseline and after 4 cycles for single-cell RNA sequencing and immune profiling, focusing on changes in T lymphocyte (T), Natural Killer cell (NK), dendritic, and macrophage subsets and correlating with clinical outcomes. Primary endpoints include adverse events (Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0(CTCAE v5.0)), objective response and local control rates (Response Evaluation Criteria in Solid Tumors Version 1.1(RECIST 1.1)), 4-cycle completion, and toxicity-related discontinuation. Secondary endpoints include disease control rate, progression-free survival (Kaplan-Meier), and dynamic immune changes. First radiological assessment occurs at 6-8 weeks post-treatment, then every 3 months until progression, loss to follow-up, or 1 year. If re-biopsy is unsafe, only peripheral blood may be collected without protocol violation. Comprehensive follow-up, data confidentiality, and missing-data handling are in place to ensure scientific validity and participant protection.

Read the detailed description

This study is a prospective, single-center, open-label, real-world observational clinical study that plans to enroll 10 to 15 patients with advanced (Stage IV) breast cancer who have failed multiple lines of prior therapy (aged 18-75 years, with ECOG performance status 0-2, and with measurable and injectable tumor lesions). It aims to preliminarily explore the antitumor activity, safety, and impact on the tumor immune microenvironment of intratumoral H101 oncolytic virus injection combined with immune checkpoint inhibitors (ICIs) in a real-world clinical setting. The study does not interfere with routine clinical decisions; the specific combination regimen (H101 intratumoral injection plus an anti-PD-1 or anti-CTLA-4 antibody) is determined by the attending physician based on the patient's condition, prior treatments, and multidisciplinary team recommendations. However, to ensure consistent observation, a standardized treatment framework is established: each cycle lasts 2-3 weeks; on day 1 of each cycle, H101 is injected intratumorally (dose stratified by lesion size according to the package insert, e.g., 5×10¹¹ VP per session with divided injections), and intravenous ICI infusion is started 7±2 days after the first injection, with a planned total of 4 cycles. To analyze biological changes before and after treatment, the study includes a systematic sampling plan: at baseline and after completion of 4 cycles, we attempt to re-biopsy the same accessible lesion whenever possible and also collect peripheral blood. These paired samples will be used for single-cell RNA sequencing and immune microenvironment analysis, focusing on changes in the composition, functional status, and differentially expressed genes of key immune cell subsets (T cells, NK cells, dendritic cells, macrophages), and correlating these changes with clinical efficacy indicators. For efficacy and safety evaluation, the primary endpoints include the incidence and severity of treatment-related adverse events (assessed by CTCAE v5.0), objective response rate and local lesion control rate (by RECIST 1.1), as well as feasibility and tolerability measured by the 4-cycle completion rate and the rate of treatment discontinuation due to toxicity. Secondary endpoints include disease control rate, progression-free survival (estimated using the Kaplan-Meier method for median survival time), and the paired dynamic changes in the above immune microenvironment markers from baseline to post-treatment. For follow-up and data collection, the first radiographic efficacy evaluation is performed 6-8 weeks after treatment completion, and then every 3 months thereafter until disease progression, loss to follow-up, or 1 year. In consideration of real-world operational practicality, if the injected lesion markedly shrinks, becomes necrotic, or cannot be safely re-biopsied after treatment, only peripheral blood samples may be collected without being considered a protocol violation. Comprehensive follow-up management, data confidentiality, and missing data handling measures are also in place to maximize the scientific rigor of the study and safeguard the rights and safety of participants.

03

Conditions studied

  • Breast Cancer (Locally Advanced or Metastatic)

Keywords

  • H101 oncolytic virus
  • immune checkpoint inhibitors
  • advanced metastatic breast cancer
  • tumor immune microenvironment
  • intratumoral injection
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This study will enroll 15 patients with advanced metastatic breast cancer presenting with multiple metastases, who have failed multiple prior lines of systemic therapy, and are aged 18 to 75 years. Subjects will be primarily recruited from the patient population at Foshan Fosun Chancheng Hospital. All eligible subjects must meet all inclusion criteria and none of the exclusion criteria.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 to 75 years, both genders;
  • confirmed breast cancer (Stage IV);
  • Disease progression after at least one line of standard systemic therapy;
  • performance status 0-2;
  • Intolerant to or refusal of standard chemotherapy;
  • At least one radiologically per 1.1 criteria;
  • At least one lesion amenable to puncture/injection (i.e., accessible for intratumoral injection);
  • Estimated ≥3 months;
  • Adequate major organ function as defined by the following laboratory values: (ANC) ≥1.5×10⁹/L, count (PLT) ≥100×10⁹/L, (Hb) ≥90 g/L, (ALT) and Aspartate aminotransferase (AST) ≤2.5× (ULN),Serum creatinine (Cr) ≤1.5× ULN;
  • Signed form;
  • Agreement to provide tumor tissue samples and peripheral blood samples before and after treatment for research purposes.。

Exclusion criteria

Exclusion Criteria:

  • Known allergy to H101 formulation, inhibitors, or any of their ;
  • Lymphocyte count \<0.5×10⁹/L;
  • Severe infection, active infection (particularly , , ), or severely status;
  • Presence of lesions that cannot be safely punctured/injected;
  • Prior treatment with PD-1/PD-L1 inhibitors with grade ≥3 immune-related adverse events that have not resolved;
  • Concurrent active other than breast cancer (except for those cured for >5 years with no evidence of recurrence);
  • Uncontrolled ;
  • Pregnant or breastfeeding wome;
  • Psychiatric disorders, cognitive impairment, or poor compliance that may interfere with study participation and completion;
  • Severe cardiac, hepatic, or renal failure;
  • Long-term immunosuppressive therapy;
  • Uncontrolled active disease.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
15 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Treatment group

    H101 (Recombinant Human Adenovirus Type 5 Injection)+Anti-Programmed Cell Death Protein 1 Antibody(Anti-PD-1 antibody) ± Anti-Cytotoxic T-Lymphocyte-Associated Protein 4 Antibody(anti-CTLA-4 antibody) H101 (Recombinant Human Adenovirus Type 5 Injection) Route of administration: Intratumoral injection Dose: Stratified dosing according to lesion size, using the dose specified in the package insert and the dose based on prior clinical experience (multipoint injection) Frequency: Once per cycle Treatment course: 2-3 weeks per cycle, for a total of 4 cycles Anti-PD-1 antibody ± anti-CTLA-4 antibody Initiation time: 7 ± 2 days after the first H101 injection Administration schedule: Once per cycle

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events

    Metric/method of measurement : Common Terminology Criteria for Adverse Events version 5.0

    Time frame: From first dose of study treatment through 30 days after the last dose (up to approximately 8-12 weeks)

  2. Objective Response Rate

    Response Evaluation Criteria in Solid Tumors version 1.1

    Time frame: 6-8 weeks after the end of treatment (after completion of 4 treatment cycles)

  3. Local Control Rate

    According to clinical and radiological assessment

    Time frame: Baseline and every 3 months up to 1 year after the end of treatment

  4. Treatment Feasibility

    Measured by completion rate and adherence rate

    Time frame: During the treatment period (up to 4 cycles, each cycle 2-3 weeks)

  5. Tolerability of the study drug in participants

    Tolerability will be assessed by the incidence, severity, and relatedness of TEAEs, and the proportion of participants who discontinue treatment due to TEAEs.

    Time frame: From first dose of study treatment through 30 days after the last dose (up to approximately 8-12 weeks)

Secondary outcomes

  1. Disease Control Rate

    Response Evaluation Criteria in Solid Tumors, version 1.1(RECIST 1.1 )

    Time frame: Baseline and up to approximately 6 months (including 6-8 weeks after the end of treatment)

  2. Progression-Free Survival

    According to clinical and radiological assessment

    Time frame: From first dose of study treatment until disease progression per RECIST v1.1 or death from any cause, whichever occurs first (up to approximately 2 years)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Lin J, Lin Z, Zhang H, et al.Recombinant human adenovirus type 5 (H101) combined with anti-PD-1 monoclonal antibody in patients with advanced melanoma after immunotherapy failure.J Clin Oncol. 2025 ASCO Annual Meeting Abstract.DOI:10.1200/JCO.2025.43.16_suppl.e21505.
  • Zhang J, Zhang Q, Liu Z, Wang J, Shi F, Su J, Wang T, Wang F. Efficacy and Safety of Recombinant Human Adenovirus Type 5 (H101) in Persistent, Recurrent, or Metastatic Gynecologic Malignancies: A Retrospective Study. Front Oncol. 2022 Apr 28;12:877155. doi: 10.3389/fonc.2022.877155. eCollection 2022. PubMed 35574359 ↗
  • Zhang Q, Zhang J, Liu Z, Wang J, Wang F, Wang T, Shi F, Su J, Zhao Y. Recombinant Human Adenovirus Type 5 (H101) Intra-Tumor Therapy in Patients with Persistent, Recurrent, or Metastatic Cervical Cancer: Genomic Profiling Relating to Clinical Efficacy. Drug Des Devel Ther. 2023 Nov 27;17:3507-3522. doi: 10.2147/DDDT.S429180. eCollection 2023. PubMed 38046281 ↗
  • Zhao Q, Xiao M, Ma J, Fu C, Gao Q, Bi Y. Reverse resistance to immune checkpoint inhibitor in a patient with recurrent cardia cancer by intratumoral injection of recombinant human adenovirus type 5: a case report and literature review. Front Oncol. 2024 Nov 11;14:1465664. doi: 10.3389/fonc.2024.1465664. eCollection 2024. PubMed 39588306 ↗
  • Duan C, Liu X. Recombinant human adenovirus type 5 administration for the treatment of malignant ascites or pleural effusion in cancer patients: a meta-analysis. Front Oncol. 2025 Sep 17;15:1592995. doi: 10.3389/fonc.2025.1592995. eCollection 2025. PubMed 41040530 ↗
  • Wang ZM, Li MK, Yang QL, Duan SX, Lou XY, Yang XY, Liu Y, Zhong YW, Qiao Y, Wang ZS, Sun L, Qian F. Recombinant human adenovirus type 5 promotes anti-tumor immunity via inducing pyroptosis in tumor endothelial cells. Acta Pharmacol Sin. 2024 Dec;45(12):2646-2656. doi: 10.1038/s41401-024-01349-x. Epub 2024 Jul 19. PubMed 39030309 ↗

Individual participant data

Plan to share: No — No, Individual Participant Data (IPD) will not be shared.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Feb 2028, 17 months later.

Of 1,192 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 138. This study's planned 17 months is below that.

Counting every sponsor, half of 1,381 studies reached it within 55 months; a quarter within 25 and three quarters within 125.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2026
First posted
Sep 30, 2026
StartEst.
Sep 9, 2026
Primary completionEst.
Feb 29, 2028
CompletionEst.
Feb 29, 2028
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07850869
Lead sponsor
Jie Yuan,MD
Responsible party
Jie Yuan,MD (Associate Chief Physician, Foshan Fosun Chancheng Hospital) — Sponsor-investigator
First posted
Sep 30, 2026
Start date
Sep 9, 2026 (estimated)
Primary completion
Feb 29, 2028 (estimated)
Completion
Feb 29, 2028 (estimated)
Last update
Sep 30, 2026

Study contacts

Jie Yuan, Doctoral degree
Contact
candlewjy@163.com
+86 13016007353
Jie Yuan
Contact
0757-82778323

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion